Further, we confirmed everolimus treatment had no effects on Rb phosphorylation (data not shown), and demonstrate that the cotargeting CDK4/6 and mTOR is an attractive targeted therapy for HNSCC. The gene discussed is MTOR; the disease is head and neck squamous cell carcinoma.